Enzo Biochem (NYSE:ENZ) Shares Down 5.6%

Enzo Biochem, Inc. (NYSE:ENZ)’s stock price dropped 5.6% during mid-day trading on Friday . The stock traded as low as $3.37 and last traded at $3.37. Approximately 1,869,964 shares traded hands during mid-day trading, an increase of 771% from the average daily volume of 214,737 shares. The stock had previously closed at $3.57.

The company has a debt-to-equity ratio of 0.05, a current ratio of 5.61 and a quick ratio of 5.12. The firm has a 50 day moving average price of $3.61.

Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings data on Monday, June 10th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. The firm had revenue of $19.66 million during the quarter. Enzo Biochem had a negative return on equity of 34.02% and a net margin of 2.49%.

In related news, major shareholder Discovery Fund Lp Harbert purchased 14,132 shares of Enzo Biochem stock in a transaction that occurred on Monday, May 20th. The stock was bought at an average cost of $3.61 per share, for a total transaction of $51,016.52. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Harbert Management Corp purchased 63,677 shares of Enzo Biochem stock in a transaction that occurred on Tuesday, May 28th. The shares were bought at an average price of $3.09 per share, with a total value of $196,761.93. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 179,927 shares of company stock valued at $563,323. 9.40% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA raised its position in Enzo Biochem by 1,298.2% during the first quarter. BNP Paribas Arbitrage SA now owns 9,242 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 8,581 shares in the last quarter. Corient Capital Partners LLC acquired a new stake in Enzo Biochem in the first quarter valued at approximately $31,000. Prudential Financial Inc. acquired a new stake in Enzo Biochem in the fourth quarter valued at approximately $33,000. Bank of New York Mellon Corp grew its holdings in Enzo Biochem by 6.0% in the fourth quarter. Bank of New York Mellon Corp now owns 218,918 shares of the medical research company’s stock valued at $609,000 after purchasing an additional 12,371 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in Enzo Biochem in the first quarter valued at approximately $36,000. Institutional investors own 67.59% of the company’s stock.

About Enzo Biochem (NYSE:ENZ)

Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.

See Also: What are some reasons analysts would give stocks a buy rating?

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.